Rchr
J-GLOBAL ID：201801015550309195   Update date: Jun. 07, 2024

Ishibashi Mariko

Ishibashi Mariko
Affiliation and department：
Nippon Medical School Department of Microbiology and Immunology

About Nippon Medical School Department of Microbiology and Immunology


Job title： senior assistant professor
Research field  (4)： Molecular biology ,  Tumor biology ,  Immunology ,  Hematology and oncology
Research keywords  (7)： Hematopoietic malignancy ,  免疫関連分子 ,  Molecular Oncology ,  Molecular biology ,  immune checkpoint ,  Cancer ,  Tumor microenvironment
Research theme for competitive and other funds  (17)：
  • 2022 - 2025 骨髄微小環境におけるSiglec-15を介した多発性骨髄腫の病態進展機序の解明
  • 2020 - 2025 Whole gamma imaging to break through the physical limitation of positron emission tomography
  • 2023 - 2024 多発性骨髄腫における抑制型樹状細胞の解明とその克服に向けて
  • 2023 - 2024 多発性骨髄腫における免疫抑制性腫瘍微小環境の改善に向けて
  • 2022 - 2023 低pH骨髄腫微小環境に起因した腫瘍関連マクロファージの誘導機序の解明
Show all
Papers (25)：
  • Mariko Ishibashi, Miwako Takahashi, Taiga Yamaya, Yoichi Imai. Current and Future PET Imaging for Multiple Myeloma. Life. 2023. 13. 8. 1701-1701
  • Ryosuke Kinoshita, Mariko Ishibashi, Hiroshi Handa, Makoto Sasaki, Yoichi Imai, Norina Tanaka, Shigeki Ito, Mika Sunakawa-Kii, Yuta Kaito, Toshio Asayama, et al. The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma. Experimental hematology. 2023. 121. 38-47
  • Wataru Nakajima, Kai Miyazaki, Masahiro Sakaguchi, Yumi Asano, Mariko Ishibashi, Tomoko Kurita, Hiroki Yamaguchi, Hiroyuki Takei, Nobuyuki Tanaka. Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA. Cancers. 2022. 14. 1. 248-248
  • Yasuko Kuribayashi-Hamada, Mariko Ishibashi, Atsushi Tatsuguchi, Toshio Asayama, Namiko Takada-Okuyama, Asaka Onodera-Kondo, Keiichi Moriya, Takehito Igarashi, Hiroyuki Onose, Sakae Tanosaki, et al. Clinicopathologic characteristics and A20 mutation in primary thyroid lymphoma. Journal of Nippon Medical School. 2022. 89. 3. 301-308
  • Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, Hideto Tamura. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells. Molecular Cancer Therapeutics. 2021. 20. 7. 1283-1294
ｍore...
MISC (49)：
  • 石橋真理子. Bone marrow immune microenvironment in pathogenesis of multiple myeloma. 月刊血液内科. 2023. 86. 5
  • 石橋真理子, 田村秀人. Characteristics of tolerogenic dendritic cells in multiple myeloma microenvironment. 日本癌学会学術総会抄録集(Web). 2023. 82nd
  • 石橋真理子, 森田林平. 骨髄腫微小環境下の樹状細胞は免疫抑制だけでなく病態進展に関与する. 日本医科大学医学会雑誌. 2023. 19. 4
  • 石橋真理子. Multiple myeloma and inflammasomes. 月刊臨床免疫・アレルギー科. 2022. 77. 6
  • 石橋真理子. 骨髄腫微小環境においてSiglec-15が抗腫瘍免疫と骨病変に及ぼす機能解析. 日本医科大学医学会雑誌. 2022. 18. 4
ｍore...
Books (4)：
  • Bone marrow immune microenvironment in pathogenesis of multiple myeloma
    2023
  • 骨髄腫とインフラマソーム
    科学評論社 臨床免疫・アレルギー科 2022
  • 多発性骨髄腫におけるanti-BCMA CAR-T療法
    科学評論社 血液内科 2019
  • Expression and function of signaling lymphocytic activation molecule (SLAM) family molecules in multiple myeloma
    2017
Lectures and oral presentations  (57)：
  • Multiple myeloma microenvironment provokes inflammasome activation in tolerogenic dendritic cells to promote disease progression.
    (第49回日本骨髄腫学会学術集会 2024)
  • The multiple myeloma microenvironment triggers inflammasome activation in tolerogenic dendritic cells to promote disease progression
    (第55 日本免疫学会学術集会 2024)
  • Tolerogenic dendritic cells alter the immune microenvironment in multiple myeloma.
    (2023)
  • 多発骨髄腫の治療戦略の確立に向けて 免疫微小環境を理解する
    (Multiple Myeloma Web Seminar (ブリストルマイヤーズ招待講演) 2023)
  • Characteristics of tolerogenic dendritic cells in multiple myeloma microenvironment.
    (第81回日本癌学会学術集会 2023)
ｍore...
Professional career (1)：
  • 博士 (理学)
Work history (4)：
  • 2022/10 - 現在 日本医科大学大学院 微生物学・免疫学 講師
  • 2022/10 - 現在 Nippon Medical School Department of Microbiology and Immunology
  • 2017/10 - 2022/09 Nippon Medical School Department of Microbiology and Immunology Research associate/ Assistant professor
  • 2010/04 - 2017/09 Nihon Medical School Department of Hematology postdoctoral fellow
Committee career (3)：
  • 2022 - 現在 日本骨髄腫学会 ホームページ委員
  • 2019/05 - 現在 日本骨髄腫学会 代議員
  • 2021 - 日本骨髄腫学会 第46回学術集会 プログラム委員
Awards (10)：
  • 2024/05 - 日本骨髄腫学会 JSM Young Investigator Award
  • 2022/05 - JSM Travel Award for 19th International Myeloma Workshop
  • 2022/05 - 日本骨髄腫学会 プレナリー演題賞
  • 2021/09 - 日本医科大学 丸山記念研究助成
  • 2021/05 - 12th JSH International Symposium best poster award APRIL Upregulation in Myeloma Cells by Immunomodulatory Drugs Promotes Aggressive Myeloma.
Show all
Association Membership(s) (4)：
THE JAPANESE SOCIETY FOR IMMUNOLOGY ,  THE JAPANESE SOCIETY OF MYELOMA ,  THE JAPANESE SOCIETY OF HEMATOLOGY ,  Japanese Cancer Association
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM